Increased total renin levels but not angiotensin-converting enzyme activity in obese patients with polycystic ovary syndrome

Medical Principles and Practice

Volumn 22, Issue 5, 2013, Pages 475-479

  Alphan, Ziynet ^a   Berberoglu, Zehra ^a   Gorar, Suheyla ^a   Candan, Zehra ^a   Aktas, Aynur ^a   Aral, Yalcin ^a   Ademoglu, Esranur ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Angiotensin converting enzyme; Polycystic ovary syndrome; Renin

Indexed keywords

ALDOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE; ESTRADIOL; FOLLITROPIN; GLUCOSE; HYDROCORTISONE; HYDROXYPROGESTERONE; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; PRORENIN; RENIN; TESTOSTERONE;

ADULT; ALDOSTERONE BLOOD LEVEL; AMENORRHEA; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PLASMA RENIN ACTIVITY; PROLACTIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TESTOSTERONE BLOOD LEVEL; WAIST HIP RATIO;

ADIPOSITY; ADULT; BODY MASS INDEX; BODY WEIGHTS AND MEASURES; FEMALE; HORMONES; HUMANS; OBESITY; POLYCYSTIC OVARY SYNDROME; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84884280614     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000351572     Document Type: Article

References (30)

1. Miller WL: Disorders of androgen synthesis-from cholesterol to dehydroepiandrosterone. Med Princ Pract 2005; 14(suppl 1):58-68.
2. Diamanti-Kandarakis E, Papavasiliou AG: Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006; 12: 324-332.
3. Poretsky L, Cataldo NA, Rosenwaks Z, et al: The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-582.
4. Nestler JE, Powers LP, Matt DW, et al: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-89.
5. Ek I, Arner P, Ryden M, et al: A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 2002; 51: 484-492.
6. Mehta PK, Griendling KK: Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97.
7. Taniyama Y, Hitomi H, Hah A: Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25: 1142-1147.
8. Hitomi H, Kiyomoto H, Nishiyama A, et al: Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007; 50: 750-755.
9. Rossi GP, Belfiore A, Bernini G, et al: Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008; 93: 2566-2571.
10. Bentley-Lewis R, Adler GK, Perlstein T: Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92: 4472-4475.
11. Engeli S, Negrel R, Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270-1277.
12. Cassis LA, Saye J, Peach MJ: Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988; 11: 591-596.
13. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A: Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-14216.
14. Goossens GH, Blaak EE, Van Baak MA: Possible involvement of the adipose tissue reninangiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003; 4: 43-55.
15. Ailhaud G, Teboul M, Massiera F: Angiotensinogen, adipocyte differentiation and fat mass enlargement. Curr Opin Clin Nutr Metab Care 2002; 5: 385-389.
16. Caprio M, Feve B, Claes A, et al: Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007; 21: 2185-2194.
17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
18. Sealey JE, Cholst I, Glorioso N, et al: Sequential changes in plasma luteinizing hormone and plasma prorenin during the menstrual cycle. J Clin Endocrinol Metab 1987; 65: 1-5.
19. Diamanti-Kandarakis E, Economou FN, Livadas S, et al: Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. Kidney Blood Press Res 2009; 32: 24-31.
20. Hacihanefioglu B, Seyisoglu H, Karsidag K, et al: Influence of insulin resistance on total renin level in normotensive women with polycystic ovary syndrome. Fertil Steril 2000; 73: 261-265.
21. Li X, Shen H, Ge X: Changes of plasma renin activity and angiotensin II levels in women with polycystic ovary syndrome ( in Chinese). Zhonghua Fu Chan Ke Za Zhi 2000; 35: 586-587.
22. Bernini GP, Bela S, Cionini R, et al: Aldosterone and renin plasma levels in young patients with polycystic ovary syndrome. Endocrine Abstr 2006; 11:P692.
23. Cascella T, Palomba S, Tauchmanova L, et al: Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2006; 91: 4395-4400.
24. Mejia-Montilla J, Reyna-Villasmil E, Torres-Cepeda D, et al: Plasma renin and aldosterone levels in obese and non-obese women with polycystic ovary syndrome (in Spanish). Endocrinol Nutr 2012; 59: 21-27.
25. Armanini D, Bordin L, Dona G, et al: Polycystic ovary syndrome: implications of measurement of plasma aldosterone, renin activity and progesterone. Steroids 2012; 77: 655-658.
26. Derkx FH, Alberda AT, Zeilmaker GH, et al: High concentrations of immunoreactive renin, prorenin and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynaecol 1987; 94: 4-9.
27. Morris RS, Wong IL, Hatch IE, et al: Prorenin is elevated in polycystic ovary syndrome and may reflect hyperandrogenism. Fertil Steril 1995; 64: 1099-1103.
28. Lenz T, Sealey JE, Lappe RW, et al: Infusion of recombinant human prorenin into rhesus monkeys: effects on hemodynamics, reninangiotensin- aldosterone axis and plasma testosterone. Am J Hypertens 1990; 3: 257-261.
29. Nguyen G, Delarue F, Burckle C, et al: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
30. Huang Y, Noble NA, Zhang J: Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007; 72: 45-52.